Defects in G protein-coupled signal transduction in human disease

Annual Review of Physiology

Volumn 58, Issue , 1996, Pages 143-170

  Spiegel, A M ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

endocrine hyperfunction; GTPase; hormone resistance; mutations; receptor

Indexed keywords

CALCITONIN RECEPTOR; CANNABINOID RECEPTOR; CHORIONIC GONADOTROPIN RECEPTOR; CORTICOTROPIN RECEPTOR; ENDOTHELIN B RECEPTOR; FOLLITROPIN RECEPTOR; GLYCOPROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HORMONE RECEPTOR; INTERMEDIN; LUTEINIZING HORMONE RECEPTOR; MONOAMINE; OPSIN; PARATHYROID HORMONE RECEPTOR; THROMBOXANE A2 RECEPTOR; THYROTROPIN RECEPTOR; VASOPRESSIN V2 RECEPTOR;

AUTOSOMAL DOMINANT DISORDER; COLOR BLINDNESS; FAMILIAL DISEASE; GENETIC DISORDER; GRAVES DISEASE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERTHYROIDISM; HYPOCALCIURIA; HYPOPARATHYROIDISM; HYPOPLASIA; LEYDIG CELL; MALE PSEUDOHERMAPHRODITISM; NEPHROGENIC DIABETES INSIPIDUS; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROTEIN DEFECT; RETINITIS PIGMENTOSA; REVIEW; THYROID ADENOMA;

EID: 0029963793     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.ph.58.030196.001043     Document Type: Review

References (90)

1. 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc. Natl. Acad. Sci. USA 88:11354-58
2. Baldwin JM. 1994. Structure and function of receptors coupled to G proteins. Curr. Opin. Cell Biol. 6:180-90
3. Bichet DG, Birnbaumer M, Lonergan M, Arthus MF, Rosenthal W, et al. 1994. Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am. J. Hum. Genet. 55:278-86
4. s/adenylyl cyclase system. Mol. Endocrinol. 8:886-94
5. 2+-sensing receptor from bovine parathyroid. Nature 366:575-80
6. 2+-sensing receptor. Am. J. Kidney Dis. 25:506-13
7. Chatziantoniou C, Ruan X, Arendshorst WJ. 1995. Defective G protein activation of the cAMP pathway in rat kidney during genetic hypertension. Proc. Natl. Acad. Sci. USA 92:2924-28
8. iα1 and the mechanism of GTP hydrolysis. Science 265:1405-12
9. Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, et al. 1994. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 264:92-95
10. Duprez L, Parma J, Van Sande J, Allgeier A, Leclère J, et al. 1994. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat. Genet. 7:396-401
11. Friedman E, Adams EF, Hoog A, Gejman PV, Carson E, et al. 1994. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J. Clin. Endocrinol. Metab. 78: 568-74
12. Godfrey P, Rahal JO, Beamer WG, Copeland NG, Jenkins NA, Mayo KE. 1993. GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat. Genet. 4:227-32
13. Govardhan CP, Oprian DD. 1994. Active site-directed inactivation of constitutively active mutants of rhodopsin. J. Biol. Chem. 269:6524-27
14. s protein from spontaneously hypertensive rats. Hypertension 24:595-99
15. Hager J, Hansen L, Vaisse C, Vionnet N, Philippi A, et al. 1995. A missense mutation in the glucagon receptor gene is associated with non-insulin-dependent diabetes mellitus. Nat. Genet. 9:299-304
16. 2 receptor in a dominantly inherited bleeding disorder. J. Clin. Invest. 94:1662-67
17. sα in patients with gain and loss of endocrine function. Nature 371:164-68
18. Iismaa TP, Biden TJ, Shine J. 1995. G Protein-Coupled Receptors, Austin, TX: Landes. 181 pp.
19. Janicic N, Pausova Z, Cole DC, Hendy GN. 1995. Insertion of an Alu sequence in the calcium-sensing receptor gene in familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Am. J. Hum. Genet. 56:880-86
20. 2 receptor gene in thirteen families with nephrogenic diabetes insipidus. Kidney. Int. 46:170-76
21. 2 vasopressin receptor. Biochemistry 32:13537-44
22. Kopp P, Van Sande J, Parma J, Duprez L, Gerber H, et al. 1995. Brief report, congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. New Engl. J. Med. 332:150-54
23. Kosugi S, Van Dop C, Geffner ME, Rabl W, Carel J-C, et al. 1995. Characterization of heterozygous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum. Mol. Genet. 4:183-88
24. Kremer H, Kraaij R, Toledo SPA, Post M, Fridman JB, et al. 1995. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nat. Genet. 9:160-64
25. Kremer H, Mariman E, Otten BJ, Moll GWJ, Stoelinga GBA, et al. 1993. Cosegregatton of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty. Hum. Mol. Genet. 2:1779-83
26. Kumaramanickavel G, Maw M, Denton MJ, John S, Srikumari CRS, et al. 1994. Missense rhodopsin mutation in a family with recessive RP. Nat. Genet. 8:10-11
27. s and stimulate adenylyl cyclase in human pituitary tumours. Nature 340:692-96
28. Latronico AC, Reincke M, Mendonca BB, Arai K, Mora P, et al. 1995. No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasm. J. Clin. Endocrinol. Metab. 80:875-77
29. Laue L, Chan WY, Hsueh AJW, Kudo M, Hsu SY, et al. 1995. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc. Natl. Acad. Sci. USA 92:1906-10
30. Laue L, Wu SM, Kudo M, Hsueh AJW, Griffin JE, et al. 1994. An inactivating mutation of the human luteinizing hormone receptor gene in familial Leydig cell hypoplasia. Mol. Biol. Cell 5:68a (Abstr. 391)
31. s-α subunit gene in nine Australian pedigrees. J. Affect. Disord. 32: 187-95
32. Lyons J, Landis CA, Harsh G, Vallar L, Grünewald K, et al. 1990. Two G protein oncogenes in human endocrine tumors. Science 249:655-59
33. Macke JP, Davenport CM, Jacobson SG, Hennessey JC, Gonzalez-Fernandez F, et al. 1993. Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin. Am. J. Hum. Genet. 53:80-89
34. Markby DW, Onrust R, Bourne HR. 1993. Separate GTP binding and GTPase activating domains of a Gα subunit. Science 262:1895-901
35. 2-receptor gene in a kindred with X-linked nephrogenic diabetes insipidus. New Engl. J Med. 328:1538-41
36. 2-adrenergic receptor. Science 264:582-86
37. Min KC, Zvygaga TA, Cypress AM, Sakmar TP. 1993. Characterization of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa: mutations on the cytoplasmic surface affect transducin activation. J. Biol. Chem. 268:9400-4
38. Nathans J. 1994. In the eye of the beholder: visual pigments and inherited variation in human vision. Cell 78:357-60
39. Neer EJ. 1995. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 80:249-57
40. Nishimoto I, Okamoto T, Matsuura Y, Takahashi S, Murayama Y, Ogata E. 1993. Alzbeimer amyloid protein precursor complexes with brain GTP-binding protein Go. Nature 362:75-79
41. Noel JP, Hamm HE, Sigler PB. 1993. The 2.2 Å crystal structure of transducin-alpha complexed with GTP gamma S. Nature 366:654-63
42. 2 receptor gene in patients with congenital nephrogenic diabetes insipidus. Biochem. Biophys. Res. Commun. 205:552-57
43. 2 vasopressin receptor mutations on stimulation of adenylyl cyclase and binding to vasopressin. J. Biol. Chem. 269:31933-37
44. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, et al. 1993. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649-51
45. Paschke R, Tonacchera M, Van Sande J, Parma J, Vassart G. 1994. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J. Clin. Endocrinol. Metab. 79:1785-89
46. Pearce SHS, Trump D, Wooding C, Besser GM, Chew SL, et al. 1994. Four novel mutations in the calcium-sensing receptor gene associated with familial benign (hypocalciuric) hypercalcemia. J. Bone Miner. Res. 9:S145 (Abstr.)
47. Perry YM, Finegold DN, Armitage MM, Ferrell RE. 1994. A missense mutation in the Ca-sensing receptor causes familial autosomal dominant hypoparathyroidism. Am. J. Hum. Genet. 55:A17 (Abstr.)
48. Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, et al. 1994. Autosomal dominant hypocalcemia caused by a calcium-sensing receptor gene mutation. Nat. Genet. 8:303-7
49. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297-303
50. Pollak MR, Wu Chou Y-H, Marx SJ, Steinmann B, Cole DEC, et al. 1994. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism: effects of mutant gene dosage on phenotype. J. Clin. Invest. 93:1108-12
51. Porcellini A, Ciullo I, Laviola L, Amabile G, Fenzi G, Avvedimento VE. 1994. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J. Clin. Endocrinol. Metab. 79:657-61
52. Puffenberger EG, Hosoda K, Washington SS, Nakao K, DeWit D, et al. 1994. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 79:1257-66
53. 2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell. Mol. Biol. 8:334-39
54. Robbins LS, Nadeau JH, Johnson KR, Kelly MA, Roselli-Rehfuss L, et al. 1993. Pigmentation phenotypes of variant extension locus alleles result from point mutations which alter MSH receptor function. Cell 72:827-34
55. Robertson GL, Scheidler JA. 1981. A newly recognized variant of familial nephrogenic diabetes insipidus distinguished by partial resistance to vasopressin (type 2). Clin. Res. 29:555A (Abstr.)
56. Rosenfeld PJ, Cowley GS, McGee TL, Sandberg MA, Berson EL, Dryja TP. 1992. A Null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. Nat. Genet. 1:209-13
57. 2 vasopressin receptor unable to stimulate adenylyl cyclase. J. Biol. Chem. 268:13030-33
58. α-i2-deficient mice. Nature Genet. 10:141-48
59. Schipani E, Kruse K, Juppner H. 1995. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268: 98-100
60. Schipani E, Weinstein LS, Bergwitz C, Lida-Klein A, Kong XF, et al. 1995. Pseudohypoparathyroidism type Ib is not caused by mutations in the coding exons of the human PTH/PTHrP receptor gene. J. Clin. Endocrinol. Metab. 80:1611-21
61. sα mutant in a patient with Albright hereditary osteodystrophy uncouples cell surface receptors from adenylyl cyclase. J. Biol. Chem. 269:25387-91
62. O in Caenorhabditis elegans. Science 267:1648-51
63. Shenker A. 1995. G protein-coupled receptor structure and function: the impact of disease-causing mutations. Baillière's Clin. Endocrinol. Metab. In press
64. Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, Cutler GB Jr. 1993. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365:652-54
65. s. J. Pediatr. 123:509-18
66. sα mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 79: 750-55
67. Spada A, Vallar L, Faglia G. 1992. G protein oncogenes in pituitary tumors. Trends Endocrinol. Metab. 3:355-60
68. Spiegel AM, Jones TLZ, Simonds WF, Weinstein LS. 1994. G Proteins. Austin, TX: Landes. 144 pp.
69. Spiegel AM, Weinstein LS, Shenker A. 1993. Abnormalities in G protein-coupled signal transduction pathways in human disease. J. Clin. Invest. 92:1119-25
70. Stein SA, Oates EL, Hall CR, Grumbles RM, Fernandez LM, et al. 1994. Identification of a point mutation in the thyrotropin receptor of the hyt/hyt hypothyroid mouse. Mol. Endocrinol. 8: 129-38
71. Strader CD, Fong TM, Tota MR, Underwood D. 1994. Structure and function of G protein-coupled receptors. Annu. Rev. Biochem. 63:101-3 2
72. Suarez F, Lebrun JJ, Lecossier D, Escoubet B, Coureau C, Silve C. 1995. Expression and modulation of the parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid in skin fibroblasts from patients with type Ib pseudohypoparathyroidism. J. Clin. Endocrinol. Metab. 80:965-70
73. Sullivan JM, Scott KM, Falls HF, Richards JE, Sieving PA. 1994. A novel rhodopsin mutation at the retinal binding site (Lys-296-Met) in ADRP. Invest. Ophthalmol. Visual Sci. 34:1149
74. Sung C-H, Davenport CM, Nathans J. 1993. Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa: clustering of functional classes along the polypeptide chain. J. Biol. Chem. 268:26645-49
75. Sunthornthepvarakul T, Gottschalk ME, Hayashi Y, Refetoff S. 1995. Resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene. New Engl. J. Med. 332:155-60
76. Tsigos C, Arai K, Hung W, Chrousos GP. 1993. Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J. Clin. Invest. 92:2458-61
77. 2 receptor gene in unrelated Japanese kindreds with nephrogenic diabetes insipidus. Biochem. Biophys. Res. Common. 197:1000-10
78. 2-adrenergic receptor in nocturnal and nonnocturnal asthma. J. Clin. Invest. 95:1635-41
79. 3-adrenergic-receptor gene. New Engl. J. Med. 333:343-47
80. Wand GS, Waltman C, Martin CS, McCaul ME, Levine MA, Wolfgang D. 1994. Differential expression of guanosine triphosphate binding proteins in men at high and low risk for the future development of alcoholism. J. Clin. Invest. 94:1004-11
81. Watson PF, French A, Pickerill AP, McIntosh RS, Weetman AP. 1995. Lack of an association between a polymorphism in the coding region of the thyrotropin receptor gene and Graves' disease. J. Clin. Endocrinol. Metab. 80: 1032-35
82. Weber A, Toppari J, Harvey RD, Klann RC, Shaw NJ, et al. 1995. Adrenocorticotropin receptor gene mutations in familial glucocorticoid deficiency: relationships with clinical features in four families. J. Clin. Endocrinol. Metab. 80:65-71
83. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. 1991. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. New Engl. J. Med. 325:1688-95
84. 2 vasopressin receptor gene of patients with X-linked nephrogenic diabetes insipidus. Hum. Mol. Genet. 3:1429-30
85. Wildin RS, Antush MJ, Bennett RL, Schoof JM, Scott CR. 1994. Heterogeneous AVPR2 gene mutations in congenital nephrogenic diabetes insipidus. Am. J. Hum. Genet. 55:266-77
86. 12 potentiates the eicosanoid pathway and is highly oncogenic in NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 90:6741-45
87. Yano K, Hidaka A, Saji M, Polymeropoulos MH, Okuno A, et al. 1994. A sporadic case of male-limited precocious puberty has the same constitutively activating point mutation in luteinizing hormone/choriogonadotropin receptor gene as familial cases. J. Clin. Endocrinol. Metab. 79:1818-23
88. Yano K, Saji M, Hidaka A, Moriya N, Okuno A, et al. 1995. A new constitutively activating point mutation in the luteinizing hormone/choriogonadotropin receptor gene in cases of male-limited precocious puberty. J. Clin. Endocrinol. Metab. In press
89. Young D, Waitches G, Birchmeier C, Fasano O, Wigler M. 1986. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 45:711-19
90. 2 vasopressin receptor gene in two pedigrees with congenital nephrogenic diabetes insipidus. J. Clin. Endocrinol. Metab. 79:361-65